T. Rowe Price Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

T. Rowe Price Associates’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-156,273	Closed	-$27M	–	2611
2015 Q1	$27M	Sell	156,273 -758,600	-83%	-$111M	0.01%	1036
2014 Q4	$105M	Buy	914,873 +680,400	+290%	+$82.4M	0.02%	606
2014 Q3	$36.6M	Buy	234,473 +57,600	+33%	+$8.35M	0.01%	934
2014 Q2	$21.8M	Buy	176,873 +13,900	+9%	+$1.54M	﹤0.01%	1103
2014 Q1	$16.9M	Buy	162,973 +2,600	+2%	+$266K	﹤0.01%	1162
2013 Q4	$14.4M	Sell	160,373 -315,500	-66%	-$25.2M	﹤0.01%	1186
2013 Q3	$31.8M	Buy	475,873 +4,600	+1%	+$317K	0.01%	961
2013 Q2	$31.2M	Buy	+471,273	New	+$27M	0.01%	944

Other funds holding SLXP

MMG

Monetary Management Group St Louis, Missouri $487M AUM 49.37% 1-Year Est. Return

T. Rowe Price Associates's SLXP Position: Q2 2015 in Review

T. Rowe Price Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 156,273 shares — an estimated $27M sold.

T. Rowe Price Associates first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $105M in Q4 2014. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

T. Rowe Price Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
T. Rowe Price Associates sold 156,273 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $27M.
T. Rowe Price Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
T. Rowe Price Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $105M in Q4 2014.
1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.